VKH
ACAD icon

Virtu KCG Holdings’s Acadia Pharmaceuticals ACAD Stock Holding History

Virtu KCG Holdings’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-23,056
Closed -$793K – 2822
2017
Q1 		$793K Sell
23,056
-33,773
-59% -$1.19M 0.02% 909
2016
Q4 		$1.64M Buy
56,829
+37,957
+201% +$1M 0.04% 413
2016
Q3 		$600K Sell
18,872
-12,704
-40% -$431K 0.01% 1196
2016
Q2 		$1.02M Buy
+31,576
New +$1.06M 0.02% 737
2016
Q1 		– Sell
-13,995
Closed -$499K – 2720
2015
Q4 		$499K Buy
13,995
+6,039
+76% +$213K 0.01% 1547
2015
Q3 		$263K Sell
7,956
-6,703
-46% -$279K ﹤0.01% 2231
2015
Q2 		$614K Buy
+14,659
New +$567K 0.01% 1304
2015
Q1 		– Sell
-8,160
Closed -$259K – 3070
2014
Q4 		$259K Sell
8,160
-37,377
-82% -$1.06M ﹤0.01% 2543
2014
Q3 		$1.13M Buy
45,537
+25,158
+123% +$588K 0.02% 858
2014
Q2 		$460K Buy
+20,379
New +$425K 0.01% 2038
2014
Q1 		– Sell
-12,589
Closed -$314K – 3476
2013
Q4 		$314K Buy
12,589
+1,429
+13% +$33.7K ﹤0.01% 2528
2013
Q3 		$306K Buy
+11,160
New +$233K ﹤0.01% 2591

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Virtu KCG Holdings's ACAD Position: Q2 2017 in Review

Virtu KCG Holdings sold out of Acadia Pharmaceuticals (ACAD) in Q2 2017, closing a stake of 23,056 shares — an estimated $793K sold.

Virtu KCG Holdings first reported a position in ACAD in Q3 2013 and held it in 12 quarters. The position peaked at $1.64M in Q4 2016. 203 funds tracked by Wall St. Rank hold ACAD as of Q2 2017.

  • Virtu KCG Holdings reported no remaining Acadia Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Virtu KCG Holdings sold 23,056 Acadia Pharmaceuticals shares in Q2 2017, an estimated $793K.
  • Virtu KCG Holdings first reported a position in Acadia Pharmaceuticals in Q3 2013 and held it in 12 quarters.
  • Virtu KCG Holdings's Acadia Pharmaceuticals position peaked at $1.64M in Q4 2016.
  • 203 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.